Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
44
TRDA Quote, Financials, Valuation and Earnings
Last price:
$11.80
Seasonality move
:
-22.18%
Day range:
$11.21 - $12.00
52-week range:
$4.93 - $12.93
Dividend yield:
0%
P/E ratio:
7.16x
P/S ratio:
19.01x
P/B ratio:
1.46x
Volume:
284.8K
Avg. volume:
227.1K
1-year change:
-2.18%
Market cap:
$446.4M
Revenue:
$25.4M
EPS (TTM):
-$3.47
Analysts' Opinion
-
Consensus RatingEntrada Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $20.00, Entrada Therapeutics, Inc. has an estimated upside of 71.23% from its current price of $11.68.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $19.00 representing -62.67% downside risk from its current price of $11.68.
Fair Value
-
According to the consensus of 7 analysts, Entrada Therapeutics, Inc. has 71.23% upside to fair value with a price target of $20.00 per share.
TRDA vs. S&P 500
-
Over the past 5 trading days, Entrada Therapeutics, Inc. has overperformed the S&P 500 by 4.42% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Entrada Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Entrada Therapeutics, Inc. revenues have been falling on a year-over-year basis for 6 quarters in a row. In the most recent quarter Entrada Therapeutics, Inc. reported revenues of $1.3M.
Earnings Growth
-
Entrada Therapeutics, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Entrada Therapeutics, Inc. reported earnings per share of -$0.94.
Enterprise value:
201M
EV / Invested capital:
0.56x
Price / LTM sales:
19.01x
EV / EBIT:
-39.53x
EV / Revenue:
7.91x
PEG ratio (5yr expected):
0.25x
EV / Free cash flow:
-1.55x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
-20.57x
Gross Profit (TTM):
$21.3M
Return On Assets:
-31.92%
Net Income Margin (TTM):
-565.48%
Return On Equity:
-38.39%
Return On Invested Capital:
-33.48%
Operating Margin:
-3249.27%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $129M | $210.8M | $25.4M | $37.4M | $1.3M | |
| Gross Profit | $126.2M | $207.1M | $21.3M | $36.4M | $413K | |
| Operating Income | -$3.2M | $47M | -$156M | -$5.9M | -$42.2M | |
| EBITDA | -$385K | $50.7M | -$151.9M | -$4.9M | -$41.3M | |
| Diluted EPS | -$0.25 | $1.91 | -$3.47 | $0.03 | -$0.94 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $298.7M | $209.9M | $369.8M | $440M | $306.3M | |
| Total Assets | $305.8M | $252.1M | $469.2M | $526.3M | $377.4M | |
| Current Liabilities | $6.7M | $22M | $158.8M | $39.5M | $24.5M | |
| Total Liabilities | $7.1M | $39.5M | $226.8M | $97.6M | $71.2M | |
| Total Equity | $298.7M | $212.6M | $242.4M | $428.7M | $306.1M | |
| Total Debt | -- | $17.5M | $60.3M | $51.6M | $46.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $139.8M | -$41.6M | -$128.5M | -$31.6M | -$32.2M | |
| Cash From Investing | -$138.4M | -$27.8M | $116.8M | $53.4M | $29.1M | |
| Cash From Financing | $21M | $103M | $887K | $1.4M | $192K | |
| Free Cash Flow | $134.2M | -$44.7M | -$129.6M | -$32.2M | -$32M | |
TRDA
Sector
Market Cap
$446.4M
$25.6M
Price % of 52-Week High
90.33%
50%
Dividend Yield
0%
0%
Shareholder Yield
0.3%
-1.62%
1-Year Price Total Return
-2.18%
-18.97%
Beta (5-Year)
--
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$11.73
200-day SMA
Buy
Level
$8.00
Bollinger Bands (100)
Buy
Level
7.65 - 11.49
Chaikin Money Flow
Buy
Level
223.8K
20-day SMA
Buy
Level
$11.26
Relative Strength Index (RSI14)
Buy
Level
54.57
ADX Line
Buy
Level
20.45
Williams %R
Neutral
Level
-45.4545
50-day SMA
Buy
Level
$10.95
MACD (12, 26)
Buy
Level
3.31
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
107K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.895)
Sell
CA Score
(Annual)
Level (-0.5626)
Buy
Beneish M-Score
(Annual)
Level (-3.5144)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.6699)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company’s Endosomal Escape Vehicle (EEV) therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through this proprietary, versatile and modular approach, Entrada is advancing a robust development portfolio of RNA- and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. The company’s oligonucleotide programs are in development for the potential treatment of people living with Duchenne who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. Entrada Therapeutics was founded by Dehua Pei in 2016 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, TRDA has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TRDA average analyst price target in the past 3 months is $20.00.
-
Where Will Entrada Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Entrada Therapeutics, Inc. share price will rise to $20.00 per share over the next 12 months.
-
What Do Analysts Say About Entrada Therapeutics, Inc.?
Analysts are divided on their view about Entrada Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Entrada Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $19.00.
-
What Is Entrada Therapeutics, Inc.'s Price Target?
The price target for Entrada Therapeutics, Inc. over the next 1-year time period is forecast to be $20.00 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TRDA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Entrada Therapeutics, Inc. is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TRDA?
You can purchase shares of Entrada Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Entrada Therapeutics, Inc. shares.
-
What Is The Entrada Therapeutics, Inc. Share Price Today?
Entrada Therapeutics, Inc. was last trading at $11.80 per share. This represents the most recent stock quote for Entrada Therapeutics, Inc.. Yesterday, Entrada Therapeutics, Inc. closed at $11.68 per share.
-
How To Buy Entrada Therapeutics, Inc. Stock Online?
In order to purchase Entrada Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get TRDA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TRDA
Sector
P/E ratio
7.16x
23.22x
PEG ratio
0.25x
-0.01x
P/B ratio
1.46x
1.80x
Price / LTM sales
19.01x
1.53x
Growth Metrics
TRDA
Sector
Revenue growth
-96.53%
3.44%
Earnings growth
-3679.47%
11.15%
Revenue (5-year growth)
--
6.46%
Earnings forecast
-$1.16
-$0.19
Profitability
TRDA
Sector
Profitability FY 2025
$21.3M
$2.4M
Return on invested capital
-33.48%
-33.43%
Return on assets
-31.92%
-29.79%
Return on equity
-38.39%
-39.31%
Earnings Date
Last Earnings Date
Feb
26
Next Earnings Date
May
7
Estimated Next Earnings Date
May
28
Balance Sheet
TRDA
Sector
Total cash
$296.4M
$24.1M
Short term investments
$318.8M
$23.8M
Total assets
$377.4M
$70.2M
Long term debt
$46.8M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
50
AXTI alert for Mar 3
AXT, Inc. [AXTI] is down 9.65% over the past day.
Buy
53
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is down 6.93% over the past day.
Sell
32
TPB alert for Mar 3
Turning Point Brands, Inc. [TPB] is down 0.87% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
